Timothy Law: Coverage for GLP-1 Drugs for Obesity is in Flux | AHIP 2024
In an interview, Timothy Law, DO, MBA, chief medical officer of Highmark, talks about the issues insurers consider when providing coverage for GLP-1 drugs like Wegovy and Zepbound that can help patients lose weight.
Coverage for GLP-1 agonist drugs is in a state of flux, Timothy Law, DO, MBA, chief medical officer of Highmark Inc., said in an interview with Managed Healthcare Executive before the annual AHIP meeting in Las Vegas. Law — along with panelists Melanie R. Jay, M.D., director of NYU Langone Comprehensive Program on Obesity Research, and Amy Meister, D.O., chief medical officer of WeightWatchers — spoke about how GLP-1 therapies are changing how the healthcare industry views prevention and treatment.
Highmark is an independent licensee of the Blue Cross Blue Shield Association with about 7 million members in Pennsylvania, Delaware, New York and West Virginia.
Here he talks about how insurers, including Highmark, are thinking about the coverage for GLP-1 drugs like Wegovy (semaglutide) and Zepbound (tirzepatide) that can help patients lose weight.
